← Back to Screener
Hologic Inc (HOLX)
Price$0.00
Value ScoreC
Growth ScoreD
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)13.91%
Price vs S&P 500 (4W)3.41%
VGM Score48.88
Market Capitalization$16.97B
P/E Ratio (Annual)30.00x
All Metrics
P/CF (Annual)16.05x
Book Value / Share (Quarterly)$23.51
P/TBV (Annual)3.35x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-5.53%
Cash Flow / Share (Quarterly)$4.29
Price vs S&P 500 (YTD)5.41%
Gross Margin (TTM)56.51%
Net Profit Margin (TTM)13.18%
EPS (TTM)$2.41
10-Day Avg Trading Volume12.56M
EPS Excl Extra (TTM)$2.41
Revenue Growth (5Y)1.66%
EPS (Annual)$2.49
ROI (Annual)7.47%
Gross Margin (Annual)56.35%
Net Profit Margin (5Y Avg)20.94%
Cash / Share (Quarterly)$10.60
P/E Basic Excl Extra (TTM)31.20x
Revenue Growth QoQ (YoY)2.54%
EPS Growth (5Y)-10.02%
P/E Normalized (Annual)30.00x
ROA (Last FY)6.28%
Revenue Growth TTM (YoY)2.17%
EBITD / Share (TTM)$3.26
ROE (5Y Avg)21.35%
Operating Margin (TTM)17.56%
Cash Flow / Share (Annual)$4.06
P/B Ratio3.24x
P/B Ratio (Quarterly)3.17x
Net Income / Employee (Annual)$80,000
EV / Revenue (TTM)4.20x
Net Interest Coverage (TTM)17.99x
ROA (TTM)6.12%
EPS Growth QoQ (YoY)-8.44%
EV / EBITDA (TTM)23.52x
EPS Incl Extra (Annual)$2.49
Current Ratio (Annual)3.75x
Quick Ratio (Quarterly)3.10x
3-Month Avg Trading Volume3.91M
52-Week Price Return23.21%
EV / Free Cash Flow (Annual)19.15x
P/E Incl Extra (TTM)31.20x
Revenue / Employee (TTM)$583,600
Tangible BV / Share (Quarterly)$21.06
P/S Ratio (Annual)4.14x
Asset Turnover (Annual)0.45x
52-Week High$76.07
Operating Margin (5Y Avg)26.65%
EPS Excl Extra (Annual)$2.49
CapEx CAGR (5Y)-0.52%
Tangible BV CAGR (5Y)26.13%
26-Week Price Return13.19%
Quick Ratio (Annual)2.87x
13-Week Price Return2.04%
Total Debt / Equity (Annual)0.50x
Current Ratio (Quarterly)4.04x
Enterprise Value$17.32B
Revenue / Share Growth (5Y)4.77%
Asset Turnover (TTM)0.46x
Book Value / Share Growth (5Y)16.60%
Revenue / Employee (Annual)$580,000
Inventory Turnover (Annual)2.63x
Pretax Margin (Annual)16.61%
Cash / Share (Annual)$9.90
3-Month Return Std Dev2.63%
Gross Margin (5Y Avg)59.57%
Net Income / Employee (TTM)$76,900
EBITDA CAGR (5Y)-8.64%
EBITDA Interim CAGR (5Y)-22.64%
ROE (Last FY)11.21%
Net Interest Coverage (Annual)10.71x
EPS Basic Excl Extra (Annual)$2.49
P/FCF (TTM)17.73x
Receivables Turnover (TTM)6.79x
EV / Free Cash Flow (TTM)18.10x
Total Debt / Equity (Quarterly)0.48x
EPS Incl Extra (TTM)$2.41
Receivables Turnover (Annual)6.83x
ROI (TTM)7.29%
P/S Ratio (TTM)4.11x
Pretax Margin (5Y Avg)25.89%
Revenue / Share (Annual)$18.02
Tangible BV / Share (Annual)$20.03
Forward P/E16.99x
Free OCF CAGR (5Y)4.10%
Price vs S&P 500 (52W)0.44%
P/E Ratio (TTM)31.20x
EPS Growth TTM (YoY)-23.76%
Year-to-Date Return2.04%
5-Day Price Return0.61%
EPS Normalized (Annual)$2.49
ROA (5Y Avg)11.04%
Net Profit Margin (Annual)13.80%
Month-to-Date Return0.56%
Cash Flow / Share (TTM)$3.14
EBITD / Share (Annual)$3.20
EPS Growth (3Y)-21.46%
Operating Margin (Annual)17.42%
LT Debt / Equity (Annual)0.50x
P/CF (TTM)15.46x
ROI (5Y Avg)13.23%
P/E Excl Extra (TTM)31.20x
LT Debt / Equity (Quarterly)0.48x
EPS Basic Excl Extra (TTM)$2.41
P/TBV (Quarterly)3.54x
P/B Ratio (Annual)2.96x
Inventory Turnover (TTM)2.57x
Pretax Margin (TTM)16.08%
Book Value / Share (Annual)$22.68
Price vs S&P 500 (13W)5.41%
Net Margin Growth (5Y)-14.11%
Beta-0.19x
P/FCF (Annual)18.76x
Revenue / Share (TTM)$18.27
ROE (TTM)11.01%
52-Week Low$54.52
vGradeC
gGradeD
mGradeB
vgmGradeC
Show chart for
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
2.78
2.78
2.78
2.78
Industry Peers — X-Ray Equipment(5)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
HOLXHologic Inc | C | D | B | $0.00 |
| GEHCGE HealthCare Technologies Inc. Common Stock | B | D | D | $62.69 |
| PHGKONINKLIJKE PHILIPS N.V. | B | D | C | $26.08 |
| BFLYButterfly Network, Inc. | F | B | B | $4.60 |
| NNOXNANO-X IMAGING LTD Ordinary Shares | D | C | D | $1.95 |
| MBAICheck-Cap Ltd. | — | — | B | $1.71 |
About
Hologic manufactures women's healthcare products across four segments: diagnostics (44% of sales), breast health (38%), surgical (16%), and skeletal health (2%). The Gen-Probe acquisition strengthened its diagnostics business. The company generates 69% of revenue from the United States, with Europe (20%), Asia (8%), and other markets contributing the remainder.